Several treatment options exist for keratinocyte carcinomas (KCs), such as electrodessication and curettage (EDC), excision, and Mohs surgery (MS). We hypothesized that in an older population treatment utilization would vary by age. Using the Medicare Current Beneficiary Survey from 2001-2010, KCs identified by ICD-9, treatments identified by CPT, and multinomial logistic regression accounting for clustering, we compared KC treatments by gender, race, history of skin cancer, KC location and type, age, comorbidities, functional status, and predicted mortality (Lee Index). Subjects with HIV infection or organ transplant were excluded. 1805 subjects with 4040 KC treatments were studied. Mean age was 77.0 (SE 0.19), and 56.4% were male. 88.2% of KCs were invasive and 53.4% were located on the head and neck. 42.0% received EDC, 38.1% excision, and 19.9% MS. No statistically significant differences were noted for the odds of receiving EDC, excision, or MS by age, comorbidities, functional status, predicted mortality, gender, race, or history of skin cancer. Excision and MS were less likely than EDC for in situ versus invasive KCs (OR 0.40 95%CI [0.28-0.59] and 0.13 [0.06-0.25], respectively). MS was less likely than excision or EDC for torso and extremity KCs versus head and neck (OR 0.18 95%CI [0.11-0.29] and 0.14 [0.08-0.22], respectively). MS was less likely than excision or EDC for subjects who noted 'excellent' health versus 'poor' (OR 0.37 95%CI [0.15-0.92] and 0.38 [0.15-0.96], respectively). Treatment utilization for KC appears to vary by tumor characteristics but not by patient characteristics. However, patient perceptions of health may play a role in the use of surgical treatment. LB1494 Alopecia areata is associated with a substantial mental health burden in US inpatients